中药消癌平抗C57BL/6小鼠Lewis肺癌肿瘤血管生成的实验研究
摘要
背景和目的:
消癌平(xiaoaiping,XAP)为中药通关藤(Marsdenia tenacissima)的提取物。中医药典记载通关藤具有清热解毒、消炎镇痛、止咳平喘等作用。现代药理学研究发现,其有效成分甾体苷和多糖具有明显的抗肿瘤活性。体外试验证实其对多种肿瘤细胞株有诱导分化、促进凋亡的作用。体内试验亦证实其能显著抑制小鼠移植瘤的生长。临床研究证实消癌平单独或联合化疗、放疗对晚期食管癌、胃癌、肠癌、肝癌、肺癌、恶性浆膜腔积液等疗效显著。但其具体抗肿瘤机制至今未明。本实验的目的在于通过观察消癌平对体内小鼠移植瘤生长和对移植瘤肿瘤血管生成的影响,进一步探讨消癌平抗肿瘤的机制。
方法:
1.以C57BL/6雌性小鼠皮下接种构建Lewis肺癌小鼠模型。将45只Lewis肺癌小鼠随机分为A、B、C三组,A组给予顺铂做阳性对照,B组给予消癌平注射液,C组予生理盐水对照。
2.治疗3周后摘眼球取血,并处死动物,切除瘤体,称瘤重量并计算抑瘤率。
3.应用免疫组化染色检测移植瘤组织中CD_(34)标记的微血管数目(MVD)。酶联免疫吸附试验检测荷瘤小鼠血清中血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)浓度。
4.以C57BL/6雌性小鼠皮下接种构建Lewis肺癌小鼠模型。将30只Lewis肺癌小鼠随机分为A、B两组,A组给予消癌平注射液,B组予生理盐水对照。治疗三周后,观察各组荷瘤小鼠生存期,并计算生命延长率。
结果:
1.与生理盐水组比较,消癌平组抑瘤率有显著差异(P<0.01),抑瘤率为15.69%。
2.与生理盐水组比较,消癌平组MvD有显著差异(p<0.01);消癌平组荷瘤小鼠血清中VEGF、bFGF含量明显低于生理盐水组(p<0.05);
3.消癌平组荷瘤小鼠生存期明显长于生理盐水组(p<0.05),生命延长率为19.16%。
结论:
中药消癌平对小鼠移植瘤有抑瘤作用并能延长荷瘤小鼠的生存时间,其抗肿瘤的作用机制可能是通过减少VEGF、bFGF表达,从而降低肿瘤MVD达到抗肿瘤新生血管生成的作用。
Objects
Xiaoaiping(XAP) isolated from the stems of Marsdenia tenacissima.The traditional Chinese medicine realized that Marsdenia tenacissima has a lot of effects in clearing away the heal,expelling superficial evils,decreaing inflamation and pain, relieving cough and asthma.The studying of pharmacology for Marsdenia tenacissima has found that steroid glycoside and polysaccharrides which were isolated from Marsdenia tenacissima,have an obvious effects against cancer recently.XAP may promote cell differentiation,induce apoptosis of cancer cells in vitro study and inhibit tumor growth in vivo experiment.Using of XAP lonely or combined with chemotherapy,radiotherapy has been confirmed a thrilling treatment of effectiveness on patients in clinical practice,including esophageal cancer,gastric carcinoma, hepatic cancer,lung cancer,malignant dropsy of serous cavity and so on. Unfortunately,the specific mechanism of curing cancer were not clear.The experiment intents to investigate the influence of XAP in Lewis lung carcinoma in C57BL/6 mice and to clarify the specific mechanism of anti-tumor.
Methods
1.Forty-five C57BL/6 female mice which injected Lewis lung carcinoma cell were randomly divided into three groups,that was group A,B,C,and with fifteen mice every group.Group A was peritoneal injected with cisplatin(DDP),Group B was peritoneal injected with XAP and Group C was peritoneal injected with NS.
2.After three week's treatment,the mice were sacrificed and taking blood from eyeballs,and the tissue of xenografted tumor was taken and weighed.
3.The level of CD_(34) in xenografted tumor and the expression of microvessel density (MVD) were detected by imrnunohistochemical image analysis.The concentration of serum VEGF,bFGF were measured by ELISA.
4.Thirty C57BL/6 female mice which injected Lewis lung carcinoma cell were randomly divided into two group.Group A was peritoneal injected with XAP and Group B was peritoneal injected with NS.The days of survival time of mice were recorded after three week's treatment.
Results
1.Compared with Group NS,there was significantly difference in xenografted tumor.The inhibition rate was 15.69%.
2.Compared with Group NS,there were significantly difference in the indexes such as MVD,concentration of serum VEGF and bFGF.
3.Compared with Group NS,there was significantly difference in survival time. The extended rate was 19.16%.
Conclusions
1.XAP can inhibit tumor growth of Lewis lung carcinoma in C57BL/6 mice.
2.XAP can prolong the survival time of C57BL/6 mice with Lewis lung carcinoma.
3.XAP may down-regulate VEGF,bFGF expression and decrease MVD to inhibit tumor angiogenesis of C57BL/6 mice with Lewis lung carcinoma
消癌平(xiaoaiping,XAP)为中药通关藤(Marsdenia tenacissima)的提取物。中医药典记载通关藤具有清热解毒、消炎镇痛、止咳平喘等作用。现代药理学研究发现,其有效成分甾体苷和多糖具有明显的抗肿瘤活性。体外试验证实其对多种肿瘤细胞株有诱导分化、促进凋亡的作用。体内试验亦证实其能显著抑制小鼠移植瘤的生长。临床研究证实消癌平单独或联合化疗、放疗对晚期食管癌、胃癌、肠癌、肝癌、肺癌、恶性浆膜腔积液等疗效显著。但其具体抗肿瘤机制至今未明。本实验的目的在于通过观察消癌平对体内小鼠移植瘤生长和对移植瘤肿瘤血管生成的影响,进一步探讨消癌平抗肿瘤的机制。
方法:
1.以C57BL/6雌性小鼠皮下接种构建Lewis肺癌小鼠模型。将45只Lewis肺癌小鼠随机分为A、B、C三组,A组给予顺铂做阳性对照,B组给予消癌平注射液,C组予生理盐水对照。
2.治疗3周后摘眼球取血,并处死动物,切除瘤体,称瘤重量并计算抑瘤率。
3.应用免疫组化染色检测移植瘤组织中CD_(34)标记的微血管数目(MVD)。酶联免疫吸附试验检测荷瘤小鼠血清中血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)浓度。
4.以C57BL/6雌性小鼠皮下接种构建Lewis肺癌小鼠模型。将30只Lewis肺癌小鼠随机分为A、B两组,A组给予消癌平注射液,B组予生理盐水对照。治疗三周后,观察各组荷瘤小鼠生存期,并计算生命延长率。
结果:
1.与生理盐水组比较,消癌平组抑瘤率有显著差异(P<0.01),抑瘤率为15.69%。
2.与生理盐水组比较,消癌平组MvD有显著差异(p<0.01);消癌平组荷瘤小鼠血清中VEGF、bFGF含量明显低于生理盐水组(p<0.05);
3.消癌平组荷瘤小鼠生存期明显长于生理盐水组(p<0.05),生命延长率为19.16%。
结论:
中药消癌平对小鼠移植瘤有抑瘤作用并能延长荷瘤小鼠的生存时间,其抗肿瘤的作用机制可能是通过减少VEGF、bFGF表达,从而降低肿瘤MVD达到抗肿瘤新生血管生成的作用。
Objects
Xiaoaiping(XAP) isolated from the stems of Marsdenia tenacissima.The traditional Chinese medicine realized that Marsdenia tenacissima has a lot of effects in clearing away the heal,expelling superficial evils,decreaing inflamation and pain, relieving cough and asthma.The studying of pharmacology for Marsdenia tenacissima has found that steroid glycoside and polysaccharrides which were isolated from Marsdenia tenacissima,have an obvious effects against cancer recently.XAP may promote cell differentiation,induce apoptosis of cancer cells in vitro study and inhibit tumor growth in vivo experiment.Using of XAP lonely or combined with chemotherapy,radiotherapy has been confirmed a thrilling treatment of effectiveness on patients in clinical practice,including esophageal cancer,gastric carcinoma, hepatic cancer,lung cancer,malignant dropsy of serous cavity and so on. Unfortunately,the specific mechanism of curing cancer were not clear.The experiment intents to investigate the influence of XAP in Lewis lung carcinoma in C57BL/6 mice and to clarify the specific mechanism of anti-tumor.
Methods
1.Forty-five C57BL/6 female mice which injected Lewis lung carcinoma cell were randomly divided into three groups,that was group A,B,C,and with fifteen mice every group.Group A was peritoneal injected with cisplatin(DDP),Group B was peritoneal injected with XAP and Group C was peritoneal injected with NS.
2.After three week's treatment,the mice were sacrificed and taking blood from eyeballs,and the tissue of xenografted tumor was taken and weighed.
3.The level of CD_(34) in xenografted tumor and the expression of microvessel density (MVD) were detected by imrnunohistochemical image analysis.The concentration of serum VEGF,bFGF were measured by ELISA.
4.Thirty C57BL/6 female mice which injected Lewis lung carcinoma cell were randomly divided into two group.Group A was peritoneal injected with XAP and Group B was peritoneal injected with NS.The days of survival time of mice were recorded after three week's treatment.
Results
1.Compared with Group NS,there was significantly difference in xenografted tumor.The inhibition rate was 15.69%.
2.Compared with Group NS,there were significantly difference in the indexes such as MVD,concentration of serum VEGF and bFGF.
3.Compared with Group NS,there was significantly difference in survival time. The extended rate was 19.16%.
Conclusions
1.XAP can inhibit tumor growth of Lewis lung carcinoma in C57BL/6 mice.
2.XAP can prolong the survival time of C57BL/6 mice with Lewis lung carcinoma.
3.XAP may down-regulate VEGF,bFGF expression and decrease MVD to inhibit tumor angiogenesis of C57BL/6 mice with Lewis lung carcinoma
引文
1.上海市疾病预防控制中心,上海市肿瘤研究所流行病学研究室.上海市市区1983-2005恶性肿瘤发病率[R].肿瘤,2008.
2.Jemal A,Siegel R,Ward E,et al.Cancer statistics,2008[J].CA Cancer J Clin,2008,58(2):71-96.
3.Liekens S,De-Clercq E,Neyts J.Angiogenesis:regulators and clinical applications[J].Biochem Pharmacol,2001,61(3):253-270.
4.高勇,王杰军,许青,等.人参皂甙Rg3抑制肿瘤新生血管形成的研究[J].第二军医大学学报,2001,22(1):40-42.
5.潘子民,叶大风,谢幸,等.人参皂苷Rg3对荷卵巢癌的严重联合免疫缺陷鼠的抗肿瘤血管生成作用的研究[J].中华妇产科杂志,2002,37(4):227-230.
6.李炜,赵旭涛,孙莉,等.六神丸抗肿瘤血管生成的实验研究[J].中医药学报,2006,34(4):25-29.
7.李炜,赵玲,孙莉,等.六神丸抗肿瘤血管生成的体外实验研究[J].山东中医杂志,2006,25(6):403-406.
8.张良,姜晓玲,郭成浩.康莱特注射液对血管生成的影响[J].肿瘤,2000,20(4):313-316.
9.李金茂,赖大年.艾迪注射液对肿瘤生长及T淋巴细胞亚群的影响[J].中国临床医药研究杂志,2003,8(7):8377-8378.
10.丁杰,廖国庆,王万川,等.艾迪对结直肠癌血管生成抑制的临床研究[J].肿瘤,2007,27(2):142-146.
11.郑兰东,夏荣龙,展鹏远,等.丹参对肝脏肿瘤发展的影响[J].医药论坛杂志,2005,26(11):35-39.
12.孔庆志,黄冬生,黄涛,等.3种中药注射剂对小鼠移植性S180肉瘤血管形成抑制作用[J].中国医院药学杂志,2003,23(11):646-648.
13.华海清,秦叔逵,王锦鸿,等.三氧化二砷抗肿瘤血管形成研究[J].世界华人消化杂志,2004,12(1):27-29.
14.张雪莹,张慧,翟延君.通关藤两个化合物的研究[J].辽宁中医药大学 学报,2007,9(3):130-130.
15.叶栋枢,韦启善,刘宝玉.乌骨藤治疗恶性肿瘤初探[J].中华肿瘤杂志,1987,9(2):126-128.
16.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药杂志,2000,34(7):12-14.
17.李茂全,沈建华,胥彬,等.消癌平对SGC27901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
18.孙珏,沈建华,朱美华,等.消癌平对人胃癌细胞治疗作用的实验研究[J].上海中医药大学学报,2000,14(2):41-43.
19.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
20.陈同生,王龙祥,王会营,等.荧光共振能量转移技术对肺腺癌活细胞消癌平诱导半胱氨酸天冬氨酸酶3活化过程的实时监测[J].中国组织工程研究与临床康复,2007,11(35):7102-7105.
21.周丹,韩大庆,刘伟,等.消癌平片抗肿瘤作用研究[J].吉林中医药,2002,22(1):57-58.
22.张开通,戚晓东,黄灵,等.重组P53腺病毒联合中药治疗小鼠腹水瘤的疗效[J].中国肿瘤生物治疗杂志,2006,13(6):466-468.
23.罗崇彬.消癌平片抗突变和抗肿瘤作用研究[J].现代医院,2007,7(9):31-32.
24.王志良,樊青霞,范魁生.消癌平临床疗效观察[J].河南医科大学学报,1994,29(1):79-80.
25.王志良,王贵吉,岳邦仪.中药通光藤治疗食管癌胃癌的临床观察(附112例报告)[J].河南肿瘤学杂志,1995,8(3):202-204.
26.李凯,邹华伟.消癌平联合化疗治疗晚期食管癌的临床观察[J].中华肿瘤防治杂志,2007,14(16):1272-1273.
27.袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J].上海医药,1996,1(6):12-13.
28.赵素斌,王如美,李守霞.消癌平治疗原发性肝癌的临床疗效[J].邯郸 医学高等专科学校学报,2005,18(5):415-416.
29.卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J].现代中西医结合杂志,2004,13(20):2690-2691.
30.山广志,刘文奇.消癌平注射液经肝动脉介入治疗原发性肝癌20例[J].临床肿瘤学杂志,2006,11(9):713-714.
31.王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
32.孙珏,沈建华,朱美华,等.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究[J].上海中医药杂志,2000,34(1):14-17.
33.范忠泽,沈建华,孙珏,等.中药消癌平针剂经肝动脉介入治疗晚期肝癌的近期疗效分析[J].实用肿瘤学杂志,1998,12(1):28-30.
34.黄振倩,谭获,王春燕,等.消癌平注射液联合化疗治疗中晚期肺癌的临床研究[J].临床肿瘤学杂志,2007,12(2):97-99.
35.杨岷,吴静,李永强,等.消癌平注射液联合放疗治疗晚期非小细胞肺癌30例[J].中医研究,2000,13(1):39-41.
36.赵晓民,侯伟,闫金玉,等.消癌平注射液治疗急性白血病6例[J].中国中医急症,2007,16(1):105-105.
37.唐域,高雅苓.高龄非小细胞肺癌的化疗49例临床分析[J].实用肿瘤学杂志,2000,14(1):36-37.
38.温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J].中国民间疗法,2003,11(6):48-48.
39.裴毅,魏淑青,杨永明,等.消癌平—生长抑素类似物治疗难治性卵巢癌的初步临床观察[J].肿瘤研究与临床,2006,18(7):469-471.
40.Patel NS,Dobbie MS,Rochester M,et al.Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.Clin Cancer Res,2006,12(16):4836-4844.
41.Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186.
42.Ferrara N,Kerbel RS.Angiogenesis as a therapeutic target.Nature,2005,438(70):967-974.
43.Saito H,Tsujitani S,Kondo A,et al.Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma[J].Surgery,1999,125(2):195-201.
44.Hanahan,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
45.Cross MJ,Claesson-Welsh L.FGF and VEGF function in angiogenesis:signalling pathways,biological responses and therapeutic inhibition[J].Trends Pharmacol Sci,2001,22(4):201-207.
46.Ferrara N,Davis-Smyth T.The biology of vascular endothelial growth factor[J].EndocrRev,1997,18(1):4-25.
47.李容,杨纯正,能冬生,等.血管内皮生长因子与肿瘤治疗[J].国外医学生理病例科学与临床分册[M].2002,22(5):475-477.
48.Shibuya M.Vascular endothelial growth factor-dependent and independent regulation of angiogenesis[J].BMB Rep,2008,41(4):278-286.
49.Poon RT,Ng IO,Lau C,et al.Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma:a prospective study[J].Ann Surg,2001,233(2):227-235.
50.Murakami M,Simons M.Fibroblast growth factor regulation of neovascularization[J].Curr Opin Hematol,2008,15(3):215-220.
51.Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis[J].Cytokine & Growth Factor Reviews,2005,16(1):159.
1.邢旺兴,程荣珍,陈斌,等.乌骨藤常见混用品种辨析[J].现代中药研究与实践,2004,18(1):33-36.
2.徐国钧,何宏贤,徐珞珊,等.中国药材学[M].上海:上海科学技术出版社,1990:254-255.
3.张雪莹,张慧,翟延君.通关藤两个化合物的研究[J].辽宁中医药大学学报,2007,9(3):130-130.
4.陈纪军,张状鑫,周俊.通光藤苷F,G,H,和I结构[J].云南植物研究,1999,21(3):369-377.
5.邢旺兴,陈斌,宓鹤鸣,等.通光藤中两个新C_(21)甾体苷类成分[J].药学学报,2004,39(4):272-275.
6.刘玉芬,孙凤英,王玲,等.乌骨藤化学成分研究[J].中成药,1998,20(9):35-36.
7.蒋毅,罗思齐.通关藤新C_(21)甾体苷的化学结构研究[J].中国医药工业杂志,1996,27(9):391-395.
8.河南省新乡市前卫制药厂.消癌平有效成分的提取及剂型制备[P].中国专利:92102027,1993-10-06.
9.邢旺兴,程荣珍,陈园斤,等.通光藤药理作用与临床应用[J].中南药学,2003,1(4):229-2311.
10.谭朝阳,雷玉萍.HPLC法测定乌骨藤及其制剂消癌平片中绿原酸的含量研究[J].中医药学刊,2004,22(7):1354-1354.
11.吴卫华,康桢,欧阳冬生,等.绿原酸的药理学研究进展[J].天然产物研究与开发,2006,18(4):691-694.
12.赖玉菡,王曙.HPLC测定通关藤中绿原酸的含量[J].华西药学杂志,2006,21(1):79-81.
13.叶栋枢,韦启善,刘宝玉.乌骨藤治疗恶性肿瘤初探[J].中华肿瘤杂志,1987,9(2):126-128.
14.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药杂志,2000,34(7):12-14.
15.李茂全,沈建华,胥彬,等.消癌平对SGC27901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
16.孙珏,沈建华,朱美华,等.消癌平对人胃癌细胞治疗作用的实验研究[J].上海中医药大学学报,2000,14(2):41-43.
17.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
18.陈同生,王龙祥,王会营,等.荧光共振能量转移技术对肺腺癌活细胞消癌平诱导半胱氨酸天冬氨酸-3活化过程的实时监测[J].中国组织工程研究与临床康复,2007,11(35):7102-7105.
19.周丹,韩大庆,刘伟,等.消癌平片抗肿瘤作用研究[J].吉林中医药,2002,22(1):57-58.
20.韩大庆,周丹,王凤梅,等.消癌平片抗肿瘤作用研究[J].中华综合临床医学杂志,2004,6(1):20-21.
21.张开通,戚晓东,黄灵,等.重组P53腺病毒联合中药治疗小鼠腹水瘤的疗效[J].中国肿瘤生物治疗杂志,2006,13(6):466-468.
22.罗崇彬.消癌平片抗突变和抗肿瘤作用研究[J].现代医院,2007,7(9):31-32.
23.王志良,樊青霞,范魁生.消癌平临床疗效观察[J].河南医科大学学报,1994,29(1):79-80.
24.王志良,王贵吉,岳邦仪.中药通光藤治疗食管癌胃癌的临床观察(附112例报告)[J].河南肿瘤学杂志,1995,8(3):202-204.
25.李凯,邹华伟.消癌平联合化疗治疗晚期食管癌的临床观察[J].中华肿瘤防治杂志,2007,14(16):1272-1273.
26.袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J].上海医药,1996,1(6):12-13.
27.赵素斌,王如美,李守霞.消癌平治疗原发性肝癌的临床疗效[J].邯郸医学高等专科学校学报,2005,18(5):415-416.
28.卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J].现代中西医结合杂志,2004,13(20):2690-2691.
29.山广志,刘文奇.消癌平注射液经肝动脉介入治疗原发性肝癌20例[J].临床肿瘤学杂志,2006,11(9):713-714.
30.王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
31.孙珏,沈建华,朱美华,等.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究[J].上海中医药杂志,2000,34(1):14-17.
32.范忠泽,沈建华,孙珏,等.中药消癌平针剂经肝动脉介入治疗晚期肝癌的近期疗效分析[J].实用肿瘤学杂志,1998,12(1):28-30.
33.黄振倩,谭获,王春燕,等.消癌平注射液联合化疗治疗中晚期肺癌的临床研究[J].临床肿瘤学杂志,2007,12(2):97-99.
34.杨岷,吴静,李永强,等.消癌平注射液联合放疗治疗晚期非小细胞肺癌30例[J].中医研究,2000,13(1):39-41.
35.赵晓民,侯伟,闰金玉,等.消癌平注射液治疗急性白血病6例[J].中国中医急症,2007,16(1):105-105.
36.唐域,高雅苓.高龄非小细胞肺癌的化疗49例临床分析[J].实用肿瘤学杂志,2000,14(1):36-37.
37.温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J].中国民间疗法,2003,11(6):48-48.
38.裴毅,魏淑青,杨永明,等.消癌平—生长抑素类似物治疗难治性卵巢癌的初步临床观察[J].肿瘤研究与临床,2006,18(7):469-471.
2.Jemal A,Siegel R,Ward E,et al.Cancer statistics,2008[J].CA Cancer J Clin,2008,58(2):71-96.
3.Liekens S,De-Clercq E,Neyts J.Angiogenesis:regulators and clinical applications[J].Biochem Pharmacol,2001,61(3):253-270.
4.高勇,王杰军,许青,等.人参皂甙Rg3抑制肿瘤新生血管形成的研究[J].第二军医大学学报,2001,22(1):40-42.
5.潘子民,叶大风,谢幸,等.人参皂苷Rg3对荷卵巢癌的严重联合免疫缺陷鼠的抗肿瘤血管生成作用的研究[J].中华妇产科杂志,2002,37(4):227-230.
6.李炜,赵旭涛,孙莉,等.六神丸抗肿瘤血管生成的实验研究[J].中医药学报,2006,34(4):25-29.
7.李炜,赵玲,孙莉,等.六神丸抗肿瘤血管生成的体外实验研究[J].山东中医杂志,2006,25(6):403-406.
8.张良,姜晓玲,郭成浩.康莱特注射液对血管生成的影响[J].肿瘤,2000,20(4):313-316.
9.李金茂,赖大年.艾迪注射液对肿瘤生长及T淋巴细胞亚群的影响[J].中国临床医药研究杂志,2003,8(7):8377-8378.
10.丁杰,廖国庆,王万川,等.艾迪对结直肠癌血管生成抑制的临床研究[J].肿瘤,2007,27(2):142-146.
11.郑兰东,夏荣龙,展鹏远,等.丹参对肝脏肿瘤发展的影响[J].医药论坛杂志,2005,26(11):35-39.
12.孔庆志,黄冬生,黄涛,等.3种中药注射剂对小鼠移植性S180肉瘤血管形成抑制作用[J].中国医院药学杂志,2003,23(11):646-648.
13.华海清,秦叔逵,王锦鸿,等.三氧化二砷抗肿瘤血管形成研究[J].世界华人消化杂志,2004,12(1):27-29.
14.张雪莹,张慧,翟延君.通关藤两个化合物的研究[J].辽宁中医药大学 学报,2007,9(3):130-130.
15.叶栋枢,韦启善,刘宝玉.乌骨藤治疗恶性肿瘤初探[J].中华肿瘤杂志,1987,9(2):126-128.
16.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药杂志,2000,34(7):12-14.
17.李茂全,沈建华,胥彬,等.消癌平对SGC27901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
18.孙珏,沈建华,朱美华,等.消癌平对人胃癌细胞治疗作用的实验研究[J].上海中医药大学学报,2000,14(2):41-43.
19.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
20.陈同生,王龙祥,王会营,等.荧光共振能量转移技术对肺腺癌活细胞消癌平诱导半胱氨酸天冬氨酸酶3活化过程的实时监测[J].中国组织工程研究与临床康复,2007,11(35):7102-7105.
21.周丹,韩大庆,刘伟,等.消癌平片抗肿瘤作用研究[J].吉林中医药,2002,22(1):57-58.
22.张开通,戚晓东,黄灵,等.重组P53腺病毒联合中药治疗小鼠腹水瘤的疗效[J].中国肿瘤生物治疗杂志,2006,13(6):466-468.
23.罗崇彬.消癌平片抗突变和抗肿瘤作用研究[J].现代医院,2007,7(9):31-32.
24.王志良,樊青霞,范魁生.消癌平临床疗效观察[J].河南医科大学学报,1994,29(1):79-80.
25.王志良,王贵吉,岳邦仪.中药通光藤治疗食管癌胃癌的临床观察(附112例报告)[J].河南肿瘤学杂志,1995,8(3):202-204.
26.李凯,邹华伟.消癌平联合化疗治疗晚期食管癌的临床观察[J].中华肿瘤防治杂志,2007,14(16):1272-1273.
27.袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J].上海医药,1996,1(6):12-13.
28.赵素斌,王如美,李守霞.消癌平治疗原发性肝癌的临床疗效[J].邯郸 医学高等专科学校学报,2005,18(5):415-416.
29.卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J].现代中西医结合杂志,2004,13(20):2690-2691.
30.山广志,刘文奇.消癌平注射液经肝动脉介入治疗原发性肝癌20例[J].临床肿瘤学杂志,2006,11(9):713-714.
31.王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
32.孙珏,沈建华,朱美华,等.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究[J].上海中医药杂志,2000,34(1):14-17.
33.范忠泽,沈建华,孙珏,等.中药消癌平针剂经肝动脉介入治疗晚期肝癌的近期疗效分析[J].实用肿瘤学杂志,1998,12(1):28-30.
34.黄振倩,谭获,王春燕,等.消癌平注射液联合化疗治疗中晚期肺癌的临床研究[J].临床肿瘤学杂志,2007,12(2):97-99.
35.杨岷,吴静,李永强,等.消癌平注射液联合放疗治疗晚期非小细胞肺癌30例[J].中医研究,2000,13(1):39-41.
36.赵晓民,侯伟,闫金玉,等.消癌平注射液治疗急性白血病6例[J].中国中医急症,2007,16(1):105-105.
37.唐域,高雅苓.高龄非小细胞肺癌的化疗49例临床分析[J].实用肿瘤学杂志,2000,14(1):36-37.
38.温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J].中国民间疗法,2003,11(6):48-48.
39.裴毅,魏淑青,杨永明,等.消癌平—生长抑素类似物治疗难治性卵巢癌的初步临床观察[J].肿瘤研究与临床,2006,18(7):469-471.
40.Patel NS,Dobbie MS,Rochester M,et al.Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.Clin Cancer Res,2006,12(16):4836-4844.
41.Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186.
42.Ferrara N,Kerbel RS.Angiogenesis as a therapeutic target.Nature,2005,438(70):967-974.
43.Saito H,Tsujitani S,Kondo A,et al.Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma[J].Surgery,1999,125(2):195-201.
44.Hanahan,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
45.Cross MJ,Claesson-Welsh L.FGF and VEGF function in angiogenesis:signalling pathways,biological responses and therapeutic inhibition[J].Trends Pharmacol Sci,2001,22(4):201-207.
46.Ferrara N,Davis-Smyth T.The biology of vascular endothelial growth factor[J].EndocrRev,1997,18(1):4-25.
47.李容,杨纯正,能冬生,等.血管内皮生长因子与肿瘤治疗[J].国外医学生理病例科学与临床分册[M].2002,22(5):475-477.
48.Shibuya M.Vascular endothelial growth factor-dependent and independent regulation of angiogenesis[J].BMB Rep,2008,41(4):278-286.
49.Poon RT,Ng IO,Lau C,et al.Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma:a prospective study[J].Ann Surg,2001,233(2):227-235.
50.Murakami M,Simons M.Fibroblast growth factor regulation of neovascularization[J].Curr Opin Hematol,2008,15(3):215-220.
51.Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis[J].Cytokine & Growth Factor Reviews,2005,16(1):159.
1.邢旺兴,程荣珍,陈斌,等.乌骨藤常见混用品种辨析[J].现代中药研究与实践,2004,18(1):33-36.
2.徐国钧,何宏贤,徐珞珊,等.中国药材学[M].上海:上海科学技术出版社,1990:254-255.
3.张雪莹,张慧,翟延君.通关藤两个化合物的研究[J].辽宁中医药大学学报,2007,9(3):130-130.
4.陈纪军,张状鑫,周俊.通光藤苷F,G,H,和I结构[J].云南植物研究,1999,21(3):369-377.
5.邢旺兴,陈斌,宓鹤鸣,等.通光藤中两个新C_(21)甾体苷类成分[J].药学学报,2004,39(4):272-275.
6.刘玉芬,孙凤英,王玲,等.乌骨藤化学成分研究[J].中成药,1998,20(9):35-36.
7.蒋毅,罗思齐.通关藤新C_(21)甾体苷的化学结构研究[J].中国医药工业杂志,1996,27(9):391-395.
8.河南省新乡市前卫制药厂.消癌平有效成分的提取及剂型制备[P].中国专利:92102027,1993-10-06.
9.邢旺兴,程荣珍,陈园斤,等.通光藤药理作用与临床应用[J].中南药学,2003,1(4):229-2311.
10.谭朝阳,雷玉萍.HPLC法测定乌骨藤及其制剂消癌平片中绿原酸的含量研究[J].中医药学刊,2004,22(7):1354-1354.
11.吴卫华,康桢,欧阳冬生,等.绿原酸的药理学研究进展[J].天然产物研究与开发,2006,18(4):691-694.
12.赖玉菡,王曙.HPLC测定通关藤中绿原酸的含量[J].华西药学杂志,2006,21(1):79-81.
13.叶栋枢,韦启善,刘宝玉.乌骨藤治疗恶性肿瘤初探[J].中华肿瘤杂志,1987,9(2):126-128.
14.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药杂志,2000,34(7):12-14.
15.李茂全,沈建华,胥彬,等.消癌平对SGC27901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
16.孙珏,沈建华,朱美华,等.消癌平对人胃癌细胞治疗作用的实验研究[J].上海中医药大学学报,2000,14(2):41-43.
17.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
18.陈同生,王龙祥,王会营,等.荧光共振能量转移技术对肺腺癌活细胞消癌平诱导半胱氨酸天冬氨酸-3活化过程的实时监测[J].中国组织工程研究与临床康复,2007,11(35):7102-7105.
19.周丹,韩大庆,刘伟,等.消癌平片抗肿瘤作用研究[J].吉林中医药,2002,22(1):57-58.
20.韩大庆,周丹,王凤梅,等.消癌平片抗肿瘤作用研究[J].中华综合临床医学杂志,2004,6(1):20-21.
21.张开通,戚晓东,黄灵,等.重组P53腺病毒联合中药治疗小鼠腹水瘤的疗效[J].中国肿瘤生物治疗杂志,2006,13(6):466-468.
22.罗崇彬.消癌平片抗突变和抗肿瘤作用研究[J].现代医院,2007,7(9):31-32.
23.王志良,樊青霞,范魁生.消癌平临床疗效观察[J].河南医科大学学报,1994,29(1):79-80.
24.王志良,王贵吉,岳邦仪.中药通光藤治疗食管癌胃癌的临床观察(附112例报告)[J].河南肿瘤学杂志,1995,8(3):202-204.
25.李凯,邹华伟.消癌平联合化疗治疗晚期食管癌的临床观察[J].中华肿瘤防治杂志,2007,14(16):1272-1273.
26.袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J].上海医药,1996,1(6):12-13.
27.赵素斌,王如美,李守霞.消癌平治疗原发性肝癌的临床疗效[J].邯郸医学高等专科学校学报,2005,18(5):415-416.
28.卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J].现代中西医结合杂志,2004,13(20):2690-2691.
29.山广志,刘文奇.消癌平注射液经肝动脉介入治疗原发性肝癌20例[J].临床肿瘤学杂志,2006,11(9):713-714.
30.王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
31.孙珏,沈建华,朱美华,等.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究[J].上海中医药杂志,2000,34(1):14-17.
32.范忠泽,沈建华,孙珏,等.中药消癌平针剂经肝动脉介入治疗晚期肝癌的近期疗效分析[J].实用肿瘤学杂志,1998,12(1):28-30.
33.黄振倩,谭获,王春燕,等.消癌平注射液联合化疗治疗中晚期肺癌的临床研究[J].临床肿瘤学杂志,2007,12(2):97-99.
34.杨岷,吴静,李永强,等.消癌平注射液联合放疗治疗晚期非小细胞肺癌30例[J].中医研究,2000,13(1):39-41.
35.赵晓民,侯伟,闰金玉,等.消癌平注射液治疗急性白血病6例[J].中国中医急症,2007,16(1):105-105.
36.唐域,高雅苓.高龄非小细胞肺癌的化疗49例临床分析[J].实用肿瘤学杂志,2000,14(1):36-37.
37.温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J].中国民间疗法,2003,11(6):48-48.
38.裴毅,魏淑青,杨永明,等.消癌平—生长抑素类似物治疗难治性卵巢癌的初步临床观察[J].肿瘤研究与临床,2006,18(7):469-471.